Multiple clinical trials have demonstrated that GLP-1 RA can significantly reduce the incidence of major adverse cardiovascular events (MACEs) in patients with T2DM, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [94]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.